Van ECK Associates Corp Reduces Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Van ECK Associates Corp lessened its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 36.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 670 shares of the company’s stock after selling 379 shares during the period. Van ECK Associates Corp’s holdings in Omnicell were worth $27,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Arizona State Retirement System lifted its holdings in shares of Omnicell by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after acquiring an additional 357 shares during the last quarter. Texas Permanent School Fund Corp lifted its stake in Omnicell by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after purchasing an additional 479 shares during the last quarter. Diversified Trust Co boosted its position in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after buying an additional 494 shares during the period. GAMMA Investing LLC grew its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in shares of Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after buying an additional 600 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Performance

NASDAQ OMCL opened at $46.60 on Friday. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -119.48, a price-to-earnings-growth ratio of 47.07 and a beta of 0.81. The company’s 50-day simple moving average is $44.15 and its two-hundred day simple moving average is $36.63.

Analyst Ratings Changes

A number of equities analysts recently issued reports on OMCL shares. Benchmark restated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. JPMorgan Chase & Co. upped their price target on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Craig Hallum lifted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Finally, Wells Fargo & Company raised their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $50.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.